OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.
February 15, 2021
4D pharma has signed a clinical trial collaboration and supply agreement with Merck and Pfizer for Bavencio (avelumab).
February 12, 2021
Exscientia has formed a partnership with the ARUK-ODDI for the development of medicines targeting neuroinflammation to treat Alzheimer’s disease.
February 10, 2021
The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers.
The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.
Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
February 03, 2021
As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.
January 29, 2021
The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.